Article

Coronado receives patents for PNT treatment, technology

Fountain Hills, AZ-Coronado Industries Inc. announced that it has received patents for its pneumatic trabeculoplasty (PNT) treatment device and procedure in China.

Fountain Hills, AZ-Coronado Industries Inc. announced that it has received patents for its pneumatic trabeculoplasty (PNT) treatment device and procedure in China.

In making the announcement, Coronado's chief executive officer, Richard Smith, said the company had meetings in New York recently with a major Beijing-based facilitator with a view to bringing the device and cost-saving benefits to the Chinese health authorities and establishing distribution in China.

"It represents an enormous market for Coronado's technology, and receipt of the patents marks another big step forward in our international marketing plans," he said in a prepared statement. "Since our meeting last week, we have had a positive response back from principals in both the national health system and the private sector. We are definitely moving forward."

Dr. Sharkey said the company was intent on establishing representation in a number of overseas markets.

"We have already begun shipping products to distributors in Italy, Spain, and Portugal and negotiations are under way to establish further distribution rights in a number of other countries. You may be sure that we shall be looking very closely into the many opportunities that China presents," he said in a prepared statement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.